To the full analysis
NRC Health stock: growth
NRCNRC Health reported $137.39M in revenue for fiscal 2025, down 4% on the prior year, up 0.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.2%
per year from 2006 to 2025, per share −0.2%
Earnings (Annual rate)
3.6%
per year from 2006 to 2025, per share −2.6%
Free cash flow (Annual rate)
5.8%
per year from 2006 to 2025, per share −0.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 0.6% | 3.0% | 6.2% |
| Revenue per share | 3.0% | 3.8% | −0.2% |
| Earnings | −20.8% | −4.1% | 3.6% |
| Earnings per share | −18.9% | 2.2% | −2.6% |
| Free cash flow | −15.5% | −1.8% | 5.8% |
| Free cash flow per share | −13.5% | −1.1% | −0.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $43.77M | $5.88M | $5.36M |
| 2007 | $48.92M | $6.84M | $12.61M |
| 2008 | $51.01M | $7.45M | $12.36M |
| 2009 | $57.69M | $8.49M | $10.76M |
| 2010 | $63.4M | $8.5M | $13.06M |
| 2011 | $75.77M | $11.56M | $15.67M |
| 2012 | $86.42M | $15.07M | $16.78M |
| 2013 | $92.59M | $15.48M | $17.13M |
| 2014 | $98.84M | $18.16M | $23.71M |
| 2015 | $102.34M | $17.61M | $18.95M |
| 2016 | $109.38M | $20.52M | $22.87M |
| 2017 | $117.56M | $22.94M | $23.27M |
| 2018 | $119.69M | $30.05M | $33.88M |
| 2019 | $127.98M | $32.41M | $36.26M |
| 2020 | $133.28M | $37.26M | $36.65M |
| 2021 | $147.95M | $37.47M | $40.83M |
| 2022 | $151.57M | $31.8M | $26.43M |
| 2023 | $148.58M | $30.97M | $22.33M |
| 2024 | $143.06M | $24.78M | $19.18M |
| 2025 | $137.39M | $11.6M | $15.74M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2023)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.